Cargando…

Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma

Several genes on chromosome 1q21 region predict a high risk of multiple myeloma (MM); however, the underlying molecular pathology remains elusive. Overexpression, amplification, or activation of SET Domain Bifurcated 1 (SETDB1), which is located on 1q21, is closely associated with poor prognosis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Jing, Chen, Xiaotong, Chen, Mengping, Hou, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967582/
https://www.ncbi.nlm.nih.gov/pubmed/35372573
http://dx.doi.org/10.1155/2022/3307873
_version_ 1784678873663799296
author Xiang, Jing
Chen, Xiaotong
Chen, Mengping
Hou, Jian
author_facet Xiang, Jing
Chen, Xiaotong
Chen, Mengping
Hou, Jian
author_sort Xiang, Jing
collection PubMed
description Several genes on chromosome 1q21 region predict a high risk of multiple myeloma (MM); however, the underlying molecular pathology remains elusive. Overexpression, amplification, or activation of SET Domain Bifurcated 1 (SETDB1), which is located on 1q21, is closely associated with poor prognosis of many human solid malignancies. In our study, upregulation of SETDB1 might indicate an unfavorable prognosis of MM using bioinformatics analysis from GEO databases and MMRF-CoMMpass. Here, increased SETDB1 expression was observed in the plasma cells from newly diagnosed multiple myeloma patients compared to those from the normal controls. Meanwhile, SETDB1 overexpression was the result of increased copy numbers of SETDB1 gene. In MM patients, the Kaplan-Meier analysis was employed to demonstrate that increased SETDB1 expression was associated with shorter overall survival (OS) and event-free survival (EFS). Besides, we conducted multifactorial cox regression analysis to state that SETDB1 expression was an independent biomarker for OS and EFS. MM patients with higher SETDB1 expression showed higher levels of beta-2 microglobulin (β2M), lactate dehydrogenase (LDH), and bone marrow biopsy plasma cells (BMPC) and lower levels of haemoglobin (HGB). Functional enrichment analysis suggested that SETDB1 could promote cell cycle progression in myeloma. Finally, we observed that SETDB1 was distinctly correlated with tumor immunity in MM. SETDB1 expression in myeloma cells was positively correlated with CD56dim natural killer cells but negatively correlated with infiltrating levels of type17 T helper cells, effector memory CD8 T cells, activated dendritic cells, and natural killer T cells from whole bone marrow (WBM) biopsies. Taken together, these results indicated that SETDB1 could be used as a novel biomarker for predicting the prognosis of MM patients.
format Online
Article
Text
id pubmed-8967582
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-89675822022-03-31 Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma Xiang, Jing Chen, Xiaotong Chen, Mengping Hou, Jian Biomed Res Int Research Article Several genes on chromosome 1q21 region predict a high risk of multiple myeloma (MM); however, the underlying molecular pathology remains elusive. Overexpression, amplification, or activation of SET Domain Bifurcated 1 (SETDB1), which is located on 1q21, is closely associated with poor prognosis of many human solid malignancies. In our study, upregulation of SETDB1 might indicate an unfavorable prognosis of MM using bioinformatics analysis from GEO databases and MMRF-CoMMpass. Here, increased SETDB1 expression was observed in the plasma cells from newly diagnosed multiple myeloma patients compared to those from the normal controls. Meanwhile, SETDB1 overexpression was the result of increased copy numbers of SETDB1 gene. In MM patients, the Kaplan-Meier analysis was employed to demonstrate that increased SETDB1 expression was associated with shorter overall survival (OS) and event-free survival (EFS). Besides, we conducted multifactorial cox regression analysis to state that SETDB1 expression was an independent biomarker for OS and EFS. MM patients with higher SETDB1 expression showed higher levels of beta-2 microglobulin (β2M), lactate dehydrogenase (LDH), and bone marrow biopsy plasma cells (BMPC) and lower levels of haemoglobin (HGB). Functional enrichment analysis suggested that SETDB1 could promote cell cycle progression in myeloma. Finally, we observed that SETDB1 was distinctly correlated with tumor immunity in MM. SETDB1 expression in myeloma cells was positively correlated with CD56dim natural killer cells but negatively correlated with infiltrating levels of type17 T helper cells, effector memory CD8 T cells, activated dendritic cells, and natural killer T cells from whole bone marrow (WBM) biopsies. Taken together, these results indicated that SETDB1 could be used as a novel biomarker for predicting the prognosis of MM patients. Hindawi 2022-03-23 /pmc/articles/PMC8967582/ /pubmed/35372573 http://dx.doi.org/10.1155/2022/3307873 Text en Copyright © 2022 Jing Xiang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Xiang, Jing
Chen, Xiaotong
Chen, Mengping
Hou, Jian
Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma
title Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma
title_full Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma
title_fullStr Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma
title_full_unstemmed Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma
title_short Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma
title_sort increased expression of setdb1 predicts poor prognosis in multiple myeloma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967582/
https://www.ncbi.nlm.nih.gov/pubmed/35372573
http://dx.doi.org/10.1155/2022/3307873
work_keys_str_mv AT xiangjing increasedexpressionofsetdb1predictspoorprognosisinmultiplemyeloma
AT chenxiaotong increasedexpressionofsetdb1predictspoorprognosisinmultiplemyeloma
AT chenmengping increasedexpressionofsetdb1predictspoorprognosisinmultiplemyeloma
AT houjian increasedexpressionofsetdb1predictspoorprognosisinmultiplemyeloma